Brainsway Ltd.
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- 66.6
- Dividend yield
- –
About Brainsway
Surgical & Medical Instruments & Apparatus, SIC 3841
BrainsWay Ltd. develops and commercializes medical devices centered on its proprietary Deep Transcranial Magnetic Stimulation technology. The company focuses on non-invasive neurostimulation systems designed to treat psychiatric and neurological conditions, alongside related hardware components and system enhancements. Its business encompasses direct product sales, system leasing, and strategic collaboration arrangements. The company primarily serves healthcare providers, including physicians, treatment operators, and clinical facilities, while interacting with third-party payors such as commercial insurers and Medicare.
BrainsWay is headquartered in Jerusalem, Israel, where it conducts executive management and administrative operations. The company operates internationally, targeting markets in the United States and abroad through a combination of direct sales personnel and independent distributor networks. It conducts clinical trials across multiple regions and maintains minority investment holdings in management service organizations. The business also depends on specialized external vendors for manufacturing components and distributes its medical systems to clinical customers globally.
Summary of the business section of Brainsway's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Brainsway Ltd.
- Founded
- 2003
- Headquarters
- Jerusalem, L3
- Address
- 16 Hartum Street Rad Tower, 14th Floor, Har Hahotzvim 9777516
- Phone
- 972 2 581-3140
- Website
- www.brainsway.com
- Employees
- 129, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- L3
- Auditor
- Kost Forer Gabbay & Kasierer, Tel-Aviv, Israel
Stock & identifiers
- Ticker
- BWAY
- Other tickers
- BRSYF
- Exchange
- Nasdaq
- IPO date
- Apr 17, 2019
- Shares outstanding
- 39M, Dec 31, 2025
- Filer category
- Accelerated filer
- Stock splits
- 2-for-1, Mar 4, 2026
- SEC CIK
- 1505065
- CUSIP
- 10501L106
- ISIN
- US10501L1061
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Gilad Moiseyev | Chief Technology Officer | 53,098 |
| Yiftach Roth | Chief Scientist | 1,074,305 |
| Colleen Hanlon | VP of Medical Affairs | 53,881 |
| Hadar Levy | Chief Executive Officer | 123,050 |
| Ido Marom | Chief Financial Officer | 51,250 |
| Naomi Rozenfeld | Chief Marketing Officer | 25,000 |
| Rayten Michal Ety Mitrany | Director | 12,500 |
| Jonathan K. Shulkin | Director | 5,851,444 |
| David Zacut | Director | 1,791,468 |
| Karen Sarid | Director | 12,500 |
| Amiram Boehm | Director | 18,750 |
| Abraham Zangen | Director | 905,963 |
| Avner Lushi | Director | 6,250 |
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 129 employees, including 53”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Apr 17, 2019 | IPO | Initial public offering priced (424B4 prospectus) |
| Apr 11, 2019 | Listing | Registration of securities on an exchange (Form 8-A) |
| May 5, 2011 | Listing | Registration of securities on an exchange (Form 8-A) |